Therefore, NRF2 activation in colon cancer, as for instance in the above studies [101,108,109,110], may impair HIPK2/p53 apoptotic activity, and favor HIPK2-dependent transcriptional program of genes promoting chemoresistance and tumor progression. The gene discussed is TP53; the disease is colonic neoplasm.